دورية أكاديمية
أعرض في EDS

Prognosis Following Sustained Virologic Response in Korean Chronic Hepatitis C Patients Treated with Sofosbuvir-Based Treatment: Data from a Multicenter Prospective Observational Study up to 7 Years.

التفاصيل البيبلوغرافية
العنوان: Prognosis Following Sustained Virologic Response in Korean Chronic Hepatitis C Patients Treated with Sofosbuvir-Based Treatment: Data from a Multicenter Prospective Observational Study up to 7 Years.
المؤلفون: Park Y; Department of Internal Medicine, Kyung Hee University School of Medicine, Seoul 02447, Republic of Korea., Na SK; Department of Internal Medicine, Inje University Sanggye Paik Hospital, Seoul 01757, Republic of Korea., Yoon JH; Department of Internal Medicine, School of Medicine, Chonnam National University Hospital, Gwangju 61469, Republic of Korea., Kim SE; Department of Internal Medicine, Hallym University College of Medicine, Anyang 14068, Republic of Korea., Park JW; Department of Internal Medicine, Hallym University College of Medicine, Anyang 14068, Republic of Korea., Kim GA; Department of Internal Medicine, Kyung Hee University School of Medicine, Seoul 02447, Republic of Korea., Lee HY; Department of Internal Medicine, Inje University Sanggye Paik Hospital, Seoul 01757, Republic of Korea., Lee YS; Department of Internal Medicine, Korea University Medical Center, Seoul 08308, Republic of Korea., Kim JH; Department of Internal Medicine, Konkuk University School of Medicine, Seoul 05030, Republic of Korea.; Research Institute of Medical Science, Konkuk University School of Medicine, Seoul 05029, Republic of Korea.
المصدر: Medicina (Kaunas, Lithuania) [Medicina (Kaunas)] 2024 Jul 14; Vol. 60 (7). Date of Electronic Publication: 2024 Jul 14.
نوع المنشور: Journal Article; Observational Study; Multicenter Study
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 9425208 Publication Model: Electronic Cited Medium: Internet ISSN: 1648-9144 (Electronic) Linking ISSN: 1010660X NLM ISO Abbreviation: Medicina (Kaunas) Subsets: MEDLINE
أسماء مطبوعة: Publication: 2018- : Basel, Switzerland : MDPI
Original Publication: Kaunas : Lietuvos gydytojų sąjunga
مواضيع طبية MeSH: Hepatitis C, Chronic*/drug therapy , Hepatitis C, Chronic*/complications , Sofosbuvir*/therapeutic use , Sustained Virologic Response* , Antiviral Agents*/therapeutic use, Humans ; Male ; Female ; Middle Aged ; Prospective Studies ; Republic of Korea/epidemiology ; Aged ; Prognosis ; Adult ; Liver Neoplasms/epidemiology ; Carcinoma, Hepatocellular/epidemiology
مستخلص: Background and Objectives : Chronic hepatitis C (CHC) can be cured with direct-acting antiviral (DAA) therapy. In Korea, sofosbuvir (SOF) and ledipasvir (LDV)/SOF were launched in 2016. Patients who achieve a sustained virologic response (SVR) following DAA treatment are predicted to have a favorable prognosis. Nevertheless, little is known regarding the prognosis of Korean CHC patients who receive SOF-based treatment and achieve SVR. Therefore, the purpose of this study was to look into the long-term outcomes for these patients. Materials and Methods : This was a prospective, multicenter observational study. CHC patients were enrolled who, following SOF or LDV/SOF treatment, had achieved SVR. The last day for follow-up was December 2023. The primary endpoint was HCC occurrence, which was checked at least once per year. Results : A total of 516 patients were included in this analysis, with a median follow-up duration of 39.0 months. Among them, 231 were male patients (44.8%), with a median age of 62.0 years. Genotypes were 1 (90, 17.4%), 2 (423, 82.0%), and 3 (3, 0.6%). The combination of SOF plus ribavirin was the most common treatment (394, 76.4%). In total, 160 patients were cirrhotic (31.0%), and the mean Child-Pugh score was 5.1. Within a maximum of 7 years, 21 patients (4.1%) developed HCC. Patients with HCC were older (69 vs. 61 years, p = 0.013) and had a higher cirrhosis incidence (81.0 vs. 28.9%, p < 0.001), higher AFP (6.0 vs. 3.3, p = 0.003) and higher APRI (0.8 vs. 0.5, p = 0.005). Age over 65 ( p = 0.016) and cirrhosis ( p = 0.005) were found to be significant risk factors for HCC by Cox regression analysis. Conclusions : Patients who achieved SVR with SOF-based treatment had a relatively favorable prognosis. However, the risk of HCC was not eliminated, especially in older and cirrhotic patients. Therefore, routine follow-up, surveillance, and early treatment are required.
References: Clin Mol Hepatol. 2022 Jan;28(1):91-104. (PMID: 34736311)
Gastroenterology. 2021 Apr;160(5):1502-1520.e1. (PMID: 33529675)
N Engl J Med. 2014 May 15;370(20):1879-88. (PMID: 24720702)
Hepatol Int. 2016 Sep;10(5):681-701. (PMID: 27229718)
N Engl J Med. 2013 May 16;368(20):1878-87. (PMID: 23607594)
Hepatol Int. 2020 Dec;14(6):1023-1033. (PMID: 33277685)
Korean J Intern Med. 2022 Nov;37(6):1167-1175. (PMID: 35618302)
J Hepatol. 2023 Jun 24;:. (PMID: 37716372)
Clin Infect Dis. 2023 May 25;:. (PMID: 37229695)
N Engl J Med. 2014 May 15;370(20):1889-98. (PMID: 24725239)
J Hepatol. 2013 Mar;58(3):495-501. (PMID: 23099187)
N Engl J Med. 2014 Apr 17;370(16):1483-93. (PMID: 24725238)
J Hepatol. 2018 Aug;69(2):461-511. (PMID: 29650333)
Clin Mol Hepatol. 2022 Apr;28(2):164-173. (PMID: 34955002)
Hepatology. 2016 Aug;64(2):405-14. (PMID: 27115523)
Clin Gastroenterol Hepatol. 2020 Oct;18(11):2554-2563.e3. (PMID: 32113892)
Gastroenterology. 2019 Jan;156(2):446-460.e2. (PMID: 30367836)
J Hepatol. 2018 Apr;68(4):663-671. (PMID: 29133244)
J Hepatol. 2014 Nov;61(1 Suppl):S58-68. (PMID: 25443346)
Hepatology. 2020 Jan;71(1):44-55. (PMID: 31222774)
BMC Cancer. 2023 Nov 25;23(1):1147. (PMID: 38007418)
Gut Liver. 2020 Nov 15;14(6):775-782. (PMID: 32000468)
N Engl J Med. 2013 May 16;368(20):1867-77. (PMID: 23607593)
Liver Int. 2017 Mar;37(3):369-376. (PMID: 27678216)
فهرسة مساهمة: Keywords: direct-acting antiviral; hepatitis C; hepatocellular carcinoma; ledipasvir; sofosbuvir; sustained virologic response
المشرفين على المادة: WJ6CA3ZU8B (Sofosbuvir)
0 (Antiviral Agents)
تواريخ الأحداث: Date Created: 20240727 Date Completed: 20240727 Latest Revision: 20240729
رمز التحديث: 20240729
مُعرف محوري في PubMed: PMC11279039
DOI: 10.3390/medicina60071132
PMID: 39064561
قاعدة البيانات: MEDLINE
الوصف
تدمد:1648-9144
DOI:10.3390/medicina60071132